Contact
searchSearch
HMP Global

Alzheimer & Dementia Related Cognitive Disorders

pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
An elderly woman sits with a doctor, both wear masks alzheimer disease agitation
Conference Coverage
AXS-05 Shows Efficacy and Safety in Agitation in Alzheimer Disease
03/19/2026
Brionna Mendoza
New data presented in a poster at the 2026 Psych Congress NP Institute in Nashville, TN, highlight the efficacy and safety of AXS-05 (dextromethorphan-bupropion) based on results from the Phase 2/3 ADVANCE-1 and Phase 3 ACCORD-1 randomized...
New data presented in a poster at the 2026 Psych Congress NP Institute in Nashville, TN, highlight the efficacy and safety of AXS-05 (dextromethorphan-bupropion) based on results from the Phase 2/3 ADVANCE-1 and Phase 3 ACCORD-1 randomized...
New data presented in a poster...
03/19/2026
Psych Congress Network
Logo of the Alzheimer's Disease and Cognitive Disorders Symposium
Press Release
HMP Global’s Popular Alzheimer’s Disease and Cognitive Disorders Symposium Spurs In-Person 2026 Meeting in Orlando
12/18/2025
More than 800 participants joined the 2025 virtual program; the December 4-6, 2026 event will deepen engagement through richer education and collaborative learning.
More than 800 participants joined the 2025 virtual program; the December 4-6, 2026 event will deepen engagement through richer education and collaborative learning.
More than 800 participants...
12/18/2025
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
From Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
person holding cannabis
Cannabis Use Requiring Acute Care Increases Dementia Risk
04/22/2025
Jolynn Tumolo
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older...
04/22/2025
Neurology
From Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
From Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network

News

pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a woman pours a pill from a pill bottle into her hand
Research Summary
Meta-Analysis Finds No Clear Sex Differences in Antipsychotic Efficacy
10/15/2026
Maria Mantas
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data...
10/15/2026
Psych Congress Network
Head in profile with brain visible and target over brain
Research Summary
Structural Connectivity–Guided iTBS Improves Early Depression Outcomes
10/08/2026
Brionna Mendoza
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
A connectivity-guided approach...
10/08/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
Only 19.1% of First-Episode Psychosis Patients Adhere to Antipsychotics
10/06/2026
Brionna Mendoza
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning...
10/06/2026
Psych Congress Network
A selection of ultraprocessed foods, including donuts, hamburgers, pizza, and fries.
News
Low-Ultraprocessed-Food Diet Linked to Lower Depression Scores
09/25/2026
Brionna Mendoza
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Reducing ultraprocessed food...
09/25/2026
Psych Congress Network
older woman with depression
Research Summary
Vortioxetine Improves Depression, Shows Mixed Cognitive Effects in Older Adults
09/23/2026
Maria Mantas
Vortioxetine was consistently associated with reduced depressive symptoms in older adults with MDD, while its effects on cognition were less consistent, according to a systematic review.
Vortioxetine was consistently associated with reduced depressive symptoms in older adults with MDD, while its effects on cognition were less consistent, according to a systematic review.
Vortioxetine was consistently...
09/23/2026
Psych Congress Network
a woman holds her hands as she looks at her computer screen
Conference Coverage
Semaglutide Linked to Fewer Cognitive Symptoms in Psychiatric Disorders
09/19/2026
Maria Mantas
Semaglutide initiation was associated with fewer clinician-recorded cognitive signs and symptoms among adults with psychiatric disorders, according to a poster presented at Psych Congress.
Semaglutide initiation was associated with fewer clinician-recorded cognitive signs and symptoms among adults with psychiatric disorders, according to a poster presented at Psych Congress.
Semaglutide initiation was...
09/19/2026
Psych Congress Network
a woman holds her head in her hands
Research Summary
Negative Expectations Linked to Brain Structure, Depression Course in MDD
09/01/2026
Maria Mantas
Negative expectations about the future were associated with differences in brain structure and a longer course of depressive illness among patients with MDD.
Negative expectations about the future were associated with differences in brain structure and a longer course of depressive illness among patients with MDD.
Negative expectations about the...
09/01/2026
Psych Congress Network
psilocybin
Research Summary
Oregon Psilocybin Program Shows Mental Health Improvements, Few Serious Reactions
08/20/2026
Maria Mantas
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s state-regulated psilocybin program reported improvements in depression, anxiety, PTSD symptoms, mental well-being, and life satisfaction over 3 months.
Participants in Oregon’s...
08/20/2026
Psych Congress Network
A pregnant woman attends her doctor's appointment
News
Untreated Maternal MDD May Outweigh SSRI Risks in Pregnancy
08/18/2026
Brionna Mendoza
Treating MDD during pregnancy should be prioritized as part of maternal and fetal health care, argued the authors of a Special Communication published in JAMA Psychiatry.
Treating MDD during pregnancy should be prioritized as part of maternal and fetal health care, argued the authors of a Special Communication published in JAMA Psychiatry.
Treating MDD during pregnancy...
08/18/2026
Psych Congress Network
a worried woman looks out a window
Research Summary
Personal Worries May Drive Mind-Wandering in Major Depression
08/14/2026
Maria Mantas
In a preregistered study of 106 adults, individuals with major depressive disorder (MDD) reported more mind-wandering than healthy controls during a continuous performance task.
In a preregistered study of 106 adults, individuals with major depressive disorder (MDD) reported more mind-wandering than healthy controls during a continuous performance task.
In a preregistered study of 106...
08/14/2026
Psych Congress Network

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
Rakesh Jain, MD, MPH
Quiz
Common Missteps in Sleep Care
10/13/2026
Maria Mantas
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
According to an interview with...
10/13/2026
Psych Congress Network
illustration of a laptop screen displaying a test
Quiz
Biomarker-Consistent Antidepressant Selection
10/13/2026
Maria Mantas
Can you recall how biomarker-consistent antidepressant treatment compared to biomarker-inconsistent treatment?
Can you recall how biomarker-consistent antidepressant treatment compared to biomarker-inconsistent treatment?
Can you recall how...
10/13/2026
Psych Congress Network
pencil erasers that spell out the word "quiz"
Quiz
iTBS Outcomes in MDD
09/15/2026
Maria Mantas
Can you recall how iBTS compared to sham in addressing clinician-rated depressive symptoms among adults with MDD?
Can you recall how iBTS compared to sham in addressing clinician-rated depressive symptoms among adults with MDD?
Can you recall how iBTS compared...
09/15/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
rTMS Function in MDD Treatment
09/09/2026
Brionna Mendoza
Test your treatment knowledge with this quiz!
Test your treatment knowledge with this quiz!
Test your treatment knowledge...
09/09/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Assessing VMAT2 Inhibitor Response
09/03/2026
Maria Mantas
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2...
09/03/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Assessing VMAT2 Inhibitor Response
09/03/2026
Maria Mantas
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2 inhibitor dosing!
Test your knowledge of VMAT2...
09/03/2026
Psych Congress Network
an illustrated laptop screen displaying a quiz
Quiz
Adjunctive Treatment Efficacy in MDD
08/26/2026
Maria Mantas
Can you recall which drug demonstrated the highest efficacy as adjunctive therapy for major depressive disorder?
Can you recall which drug demonstrated the highest efficacy as adjunctive therapy for major depressive disorder?
Can you recall which drug...
08/26/2026
Psych Congress Network
pencil erasers that spell out the word "quiz"
Quiz
Citalopram Dosing in Older Adults
08/25/2026
Maria Mantas
What is the recommended dosage of citalopram for older patients? Test your prescribing knowledge with this quiz!
What is the recommended dosage of citalopram for older patients? Test your prescribing knowledge with this quiz!
What is the recommended dosage...
08/25/2026
Psych Congress Network
Chelsie Monroe Expert Insights Quiz
Expert Insights Quiz
Distinguishing EDS From Fatigue
08/03/2026
Maria Mantas
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can help clinicians differentiate fatigue from excessive daytime sleepiness in clinical practice?
What key characteristics can...
08/03/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Pharmacologic Treatment for Adolescent MDD
07/23/2026
Maria Mantas
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA guideline recommends? Test yourself with this quick quiz!
Can you recall what the APA...
07/23/2026
Psych Congress Network

Perspectives

marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
Leslie Citrome, MD
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psych Congress Network
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Paul Schulz, MD
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
Marc E. Agronin, MD
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Marc E. Agronin, MD
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Kevin Williams, MS, MPAS, PA-C
Videos
Engaging Patients and Care Partners in Tardive Dyskinesia Assessment
10/05/2026
Kevin Williams, MS, MPAS, PA-C
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Psych Congress PA Institute...
10/05/2026
Psych Congress Network
Kevin Williams, MS, MPAS, PA-C
Videos
Engaging Patients and Care Partners in Tardive Dyskinesia Assessment
10/05/2026
Kevin Williams, MS, MPAS, PA-C
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Psych Congress PA Institute...
10/05/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Conference Insights
Refining the Diagnosis When MDD Treatment Falls Short
10/05/2026
Kristian Dambrino, DNP, PMHNP, MSN
Kristian Dambrino, DNP, PMHNP-BC, offers a framework for pinpointing when antidepressant nonresponse in MDD may be a byproduct of misdiagnosis.
Kristian Dambrino, DNP, PMHNP-BC, offers a framework for pinpointing when antidepressant nonresponse in MDD may be a byproduct of misdiagnosis.
Kristian Dambrino, DNP,...
10/05/2026
Psych Congress Network
Michael Asbach, DMsc, PA-C
Conference Insights
Rethinking MDD Through Glutamate and Neuroplasticity
09/22/2026
Michael Asbach, DMSc, PA-C
Michael Asbach, DMSc, PA-C, Clinical Editor, Psych Congress Journal, explores key concepts from his Psych Congress 2026 session, “Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?”
Michael Asbach, DMSc, PA-C, Clinical Editor, Psych Congress Journal, explores key concepts from his Psych Congress 2026 session, “Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?”
Michael Asbach, DMSc, PA-C,...
09/22/2026
Psych Congress Network
Vladimir Maletic presents on stage
Videos
Dr Vladimir Maletic Memorial Scholarship Recipient Reflects on His Legacy of Compassionate, Patient-Centered Care
09/19/2026
The Dr Vladimir Maletic Memorial Scholarship was established to honor the life, legacy, and lasting influence of Dr Vladimir Maletic, a beloved member of the Psych Congress community and exceptional clinician and educator.
The Dr Vladimir Maletic Memorial Scholarship was established to honor the life, legacy, and lasting influence of Dr Vladimir Maletic, a beloved member of the Psych Congress community and exceptional clinician and educator.
The Dr Vladimir Maletic Memorial...
09/19/2026
Psych Congress Network
Julie Carbray, PhD, PMHNP-BC, and James Greenblatt, MD
Videos
First-Line Decisions in ADHD: Lifestyle Modification or Medication?
09/18/2026
Julie Carbray PhD, PMHNP-BC, PMHCNS-BC, FAAN; James Greenblatt, MD
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Julie Carbray, PhD, PMHNP-BC,...
09/18/2026
Psych Congress Network
James Greenblatt, MD
Videos
Incorporating Integrative Approaches Into Psychiatric Care
08/05/2026
James Greenblatt, MD
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
James Greenblatt, MD, discusses where lifestyle, nutritional, and functional medicine strategies may help address gaps in conventional psychiatric care.
James Greenblatt, MD, discusses...
08/05/2026
Psych Congress Network
Craig Chepke and Kevin Williams
Major Depressive Disorder Insights
Aligning Patient Goals With Novel Mechanisms in MDD Anhedonia Treatment
07/28/2026
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how clinicians can align major depressive disorder (MDD) treatment goals with patients’ lived experience of anhedonia.
Craig Chepke, MD, DFAPA, and...
07/28/2026
Psych Congress Network
Arwen Podesta, MD, DFAPA, DFASAM
Videos
Improving Alcohol Use Disorder Care With Pharmacologic Treatment
07/24/2026
Arwen Podesta, MD
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN, Arwen Podesta, MD, DFAPA, DFASAM, discusses how medication-assisted therapy (MAT) may improve patient outcomes in alcohol use disorder (AUD).
In this conversation with PCN,...
07/24/2026
Psych Congress Network
Jill Harkavy-Friedman, PhD
Videos
Taking a Comprehensive Approach to Suicide Risk Assessment in Clinical Practice
07/20/2026
Jill Harkavy-Friedman, PhD
Jill Harkavy-Friedman, PhD, walks clinicians through what a comprehensive assessment of suicide risk looks like in clinical practice.
Jill Harkavy-Friedman, PhD, walks clinicians through what a comprehensive assessment of suicide risk looks like in clinical practice.
Jill Harkavy-Friedman, PhD,...
07/20/2026
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Desiree Matthews, PHMNP-BC; Amber Hoberg, MSN, APRN, PMHNP-BC
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use